Literature DB >> 26474700

Functional synergism of Human Defensin 5 and Human Defensin 6.

Aiping Zhao1, Wuyuan Lu2, Erik de Leeuw3.   

Abstract

The gut epithelium is critically involved in maintaining intestinal immune homeostasis. Acting as a physical barrier, it separates the intestinal microflora from cells of the immune system. In addition to its barrier function, the intestinal epithelium expresses defensins, natural, endogenous antimicrobial peptides. In humans, specialized epithelial cells, termed Paneth cells, located primarily in the small intestine express two defensins, Human Defensin-5 (HD-5) and Human Defensin-6 (HD-6). Previously, we have shown that HD-5 potently kills bacteria and induces secretion of interleukin-8 by intestinal epithelial cells. We show that HD-6 specifically and synergistically enhances the HD-5-induced IL-8 secretion, but does not alter its anti-bacterial activity. Further, we find that HD-5 decreases the trans-epithelial electrical resistance of intestinal epithelial cells and that HD-6 negates this effect of HD-5. Published by Elsevier Inc.

Entities:  

Keywords:  Human defensin 5; Human defensin 6; Interleukin 8; Intestinal epithelium

Mesh:

Substances:

Year:  2015        PMID: 26474700     DOI: 10.1016/j.bbrc.2015.10.035

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

Review 1.  The immunology of host defence peptides: beyond antimicrobial activity.

Authors:  Robert E W Hancock; Evan F Haney; Erin E Gill
Journal:  Nat Rev Immunol       Date:  2016-04-18       Impact factor: 53.106

Review 2.  Microbiota and Immune-Mediated Skin Diseases-An Overview.

Authors:  Adrian Catinean; Maria Adriana Neag; Andrei Otto Mitre; Corina Ioana Bocsan; Anca Dana Buzoianu
Journal:  Microorganisms       Date:  2019-08-21

Review 3.  Antimicrobial Peptides and Their Therapeutic Potential for Bacterial Skin Infections and Wounds.

Authors:  Anja Pfalzgraff; Klaus Brandenburg; Günther Weindl
Journal:  Front Pharmacol       Date:  2018-03-28       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.